{"id":"W4221044986","doi":"10.1038/s41591-022-01731-4","title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemoimmunotherapy; Oncology; Cytokine release syndrome; Phases of clinical research; Lymphoma; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00381554,0.0004709228,0.0009719207,0.000546395,0.0005779178,0.00002016081,0.0007344899,0.000397447,0.02376741],"category_scores_gemma":[0.0007745428,0.0002923662,0.0002590406,0.00146785,0.0002718299,0.00006187431,0.0002669104,0.003310421,0.00006071825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005783987,"about_ca_system_score_gemma":0.0004603553,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000886745,"about_ca_topic_score_gemma":0.0002268306,"domain_scores_codex":[0.9945062,0.0006697564,0.0007690532,0.0007827297,0.002352317,0.0009199539],"domain_scores_gemma":[0.9970493,0.000879202,0.0002659836,0.001304695,0.0001671449,0.0003336361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4365458,0.02829088,0.002197437,0.0001882071,0.0007703573,0.003526784,0.007533842,0.00004949286,0.06248479,0.0009104844,0.1279146,0.3295873],"study_design_scores_gemma":[0.4147342,0.01269776,0.0008754396,0.00004716363,0.0001116345,0.0001242055,0.0006361334,0.0002926471,0.005333923,0.0003793213,0.5645286,0.0002389664],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9435934,0.01777083,0.00002817847,0.0266247,0.00201134,0.003069433,0.0001022562,0.000123374,0.006676436],"genre_scores_gemma":[0.96198,0.005406964,0.00003029411,0.008045199,0.003747986,0.0004529779,0.0003623013,0.0001132529,0.01986105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.436614,"threshold_uncertainty_score":0.9999529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02147039958810337,"score_gpt":0.3415673981146957,"score_spread":0.3200969985265923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}